1
|
Fridman Kogan Z, Nahum Fridland S, Ganer Herman H, Miremberg H, Bustan M, Schreiber L, Kovo M. Postpartum antihypertensive treatment: Is there a correlation to placental lesions? Arch Gynecol Obstet 2024; 310:453-459. [PMID: 37902838 DOI: 10.1007/s00404-023-07263-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/28/2023] [Accepted: 10/09/2023] [Indexed: 11/01/2023]
Abstract
OBJECTIVE We aimed to examine the association of clinical risk factors and placental lesions, in gestations complicated with preeclampsia, with the need for antihypertensive treatment in the early postpartum period. METHODS The computerized files and placental reports of all singleton deliveries at 24.0-42.0 weeks complicated by preeclampsia were reviewed between January 2013 and October 2020. Obstetric characteristics and placental lesions were compared between patients who required antihypertensive treatment in the early postpartum period and those who did not (control group). Placentas were classified into maternal and fetal malperfusion lesions and inflammatory responses. RESULTS As compared to controls (n = 200), the anti-hypertensive treatment group (n = 95) was characterized by increased rates of preterm birth, preeclampsia with severe features, and cesarean delivery (p < 0.001 for all). More placental hematomas (p = 0.01) and placental maternal vascular lesions (p = 0.03) were observed in the antihypertensive treatment group as compared to controls. In adjusted logistic regression analysis, gestational age (OR 0.86, 95% CI 0.79-0.93, p = 0.001) and preeclampsia with severe features (OR 8.89, 95% CI 3.18-14.93 p < 0.001) were found to be independently associated with the need for postpartum antihypertensive treatment. CONCLUSION Placental vascular lesions are more common in preeclamptic patients who need postpartum antihypertensive treatment, yet only early onset of preeclampsia with severe features was found to be independently associated with antihypertensive treatment in the early postpartum period.
Collapse
Affiliation(s)
- Zviya Fridman Kogan
- Department of Obstetrics and Gynecology, Edith Wolfson Medical Center, Holon, Israel, Tel Aviv, Israel
- Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
| | - Shir Nahum Fridland
- Department of Obstetrics and Gynecology, Edith Wolfson Medical Center, Holon, Israel, Tel Aviv, Israel
- Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
| | - Hadas Ganer Herman
- Department of Obstetrics and Gynecology, Edith Wolfson Medical Center, Holon, Israel, Tel Aviv, Israel
- Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
| | - Hadas Miremberg
- Department of Obstetrics and Gynecology, Edith Wolfson Medical Center, Holon, Israel, Tel Aviv, Israel
- Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
| | - Mor Bustan
- Department of Obstetrics and Gynecology, Edith Wolfson Medical Center, Holon, Israel, Tel Aviv, Israel
- Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
| | - Letizia Schreiber
- Department of Pathology, Edith Wolfson Medical Center, Holon, Israel, Tel Aviv, Israel
- Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
| | - Michal Kovo
- Department of Obstetrics and Gynecology, Meir Medical Center, Kfar-Saba, Israel.
- Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
| |
Collapse
|
2
|
Razzak R, Shivkumar PV. Early Prediction of Hypertensive Diseases of Pregnancy by Using Combined Screening Methods in a Rural Population. Cureus 2023; 15:e50624. [PMID: 38226112 PMCID: PMC10789305 DOI: 10.7759/cureus.50624] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 12/16/2023] [Indexed: 01/17/2024] Open
Abstract
INTRODUCTION The most frequent medical issue during pregnancy is hypertension, which can complicate up to 10% to 15% of pregnancies worldwide. An estimated 14% of all maternal fatalities worldwide are thought to be caused by hypertensive disease of pregnancy, one of the main causes of maternal and fetal morbidity and mortality. Despite the fact that maternal mortality is substantially lower in high-income countries than in low- and middle-income countries, hypertension is still one of the leading causes of maternal death globally. Maternal mortality associated with hypertension fluctuated between 0.08 and 0.42 per 100,000 births between 2009 and 2015. In India, the estimated overall pooled prevalence of HDP was determined to be one out of 11 women, or 11% (95% CI, 5%-17%). Despite various government programs, there is still a high prevalence of hypertension, which calls for stakeholders and healthcare professionals to focus on providing both therapeutic and preventive care. The best solution is to concentrate more on the early detection of pregnancy-related hypertension and to guarantee its universal application so that proper care can be carried out to prevent maternal and fetal morbidity. AIM To estimate the predictive value of the combination of maternal characteristics, i.e., mean arterial pressure (MAP), biophysical evaluation (uterine artery Doppler), and biochemical markers (pregnancy-associated plasma protein A (PAPP-A)), in the first trimester of pregnancy for hypertensive diseases of pregnancy. METHODOLOGY It was a prospective observational study of longitudinal variety that took over 18 months in a tertiary care rural hospital. The number of women admitted to the hospital for labor care during 2019 was 5261. A total of 513 were diagnosed with hypertensive illnesses during pregnancy. At a prevalence rate of 10%, we calculated a sample size of 350 to achieve a sensitivity of 85% with an absolute error of 12.5% at a 95% CI. Maternal histories, such as age, education, socio-economic status, gravidity, and BMI, were taken along with three parameters, i.e., MAP, which was significant above 90 mmHg, uterine artery Doppler, which was taken significant above 1.69, and serum PAPP-A, which was significant at less than 0.69 ml/IU. OBSERVATION AND RESULTS We have found that the following are associated with the prediction of hypertension: among the maternal characteristics are advanced age >35 years, presence of body edema, and urine proteins along with MAP, uterine artery pulsatility index (UtA-PI), and PAPP-A are significant. The predictive accuracy of the combination of MAP, UtA-PI, and PAPP-A is also significant. We also found that there is a significant increase in cesarean sections and NICU admissions in hypertensive patients. CONCLUSION A combination of screening parameters, including MAP, UtA-PI, and PAPP-A, to predict early hypertensive disease of pregnancy is developed and tested.
Collapse
Affiliation(s)
- Ruhida Razzak
- Obstetrics and Gynecology, Mahatma Gandhi Institute of Medical Sciences, Wardha, IND
| | - Poonam V Shivkumar
- Obstetrics and Gynecology, Mahatma Gandhi Institute of Medical Sciences, Wardha, IND
| |
Collapse
|
3
|
De Borre M, Che H, Yu Q, Lannoo L, De Ridder K, Vancoillie L, Dreesen P, Van Den Ackerveken M, Aerden M, Galle E, Breckpot J, Van Keirsbilck J, Gyselaers W, Devriendt K, Vermeesch JR, Van Calsteren K, Thienpont B. Cell-free DNA methylome analysis for early preeclampsia prediction. Nat Med 2023; 29:2206-2215. [PMID: 37640858 DOI: 10.1038/s41591-023-02510-5] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/13/2022] [Accepted: 07/22/2023] [Indexed: 08/31/2023]
Abstract
Preeclampsia (PE) is a leading cause for peripartal morbidity, especially if developing early in gestation. To enable prophylaxis in the prevention of PE, pregnancies at risk of PE must be identified early-in the first trimester. To identify at-risk pregnancies we profiled methylomes of plasma-derived, cell-free DNA from 498 pregnant women, of whom about one-third developed early-onset PE. We detected DNA methylation differences between control and PE pregnancies that enabled risk stratification at PE diagnosis but also presymptomatically, at around 12 weeks of gestation (range 9-14 weeks). The first-trimester risk prediction model was validated in an external cohort collected from two centers (area under the curve (AUC) = 0.75) and integrated with routinely available maternal risk factors (AUC = 0.85). The combined risk score correctly predicted 72% of patients with early-onset PE at 80% specificity. These preliminary results suggest that cell-free DNA methylation profiling is a promising tool for presymptomatic PE risk assessment, and has the potential to improve treatment and follow-up in the obstetric clinic.
Collapse
Affiliation(s)
- Marie De Borre
- Laboratory for Functional Epigenetics, Department of Human Genetics, KU Leuven, Leuven, Belgium
- Center for Human Genetics, University Hospitals Leuven, University of Leuven, Leuven, Belgium
| | - Huiwen Che
- Laboratory for Functional Epigenetics, Department of Human Genetics, KU Leuven, Leuven, Belgium
| | - Qian Yu
- Laboratory for Functional Epigenetics, Department of Human Genetics, KU Leuven, Leuven, Belgium
| | - Lore Lannoo
- Department of Obstetrics and Gynaecology, University Hospitals Leuven, Leuven, Belgium
| | - Kobe De Ridder
- Laboratory for Functional Epigenetics, Department of Human Genetics, KU Leuven, Leuven, Belgium
| | - Leen Vancoillie
- Center for Human Genetics, University Hospitals Leuven, University of Leuven, Leuven, Belgium
| | - Pauline Dreesen
- Faculty of Medicine and Life Science, Hasselt University, Hasselt, Belgium
| | - Mika Van Den Ackerveken
- Laboratory for Functional Epigenetics, Department of Human Genetics, KU Leuven, Leuven, Belgium
| | - Mio Aerden
- Laboratory for Functional Epigenetics, Department of Human Genetics, KU Leuven, Leuven, Belgium
- Center for Human Genetics, University Hospitals Leuven, University of Leuven, Leuven, Belgium
| | - Eva Galle
- Laboratory for Functional Epigenetics, Department of Human Genetics, KU Leuven, Leuven, Belgium
| | - Jeroen Breckpot
- Center for Human Genetics, University Hospitals Leuven, University of Leuven, Leuven, Belgium
| | | | | | - Koen Devriendt
- Center for Human Genetics, University Hospitals Leuven, University of Leuven, Leuven, Belgium
| | - Joris Robert Vermeesch
- Center for Human Genetics, University Hospitals Leuven, University of Leuven, Leuven, Belgium
| | - Kristel Van Calsteren
- Department of Obstetrics and Gynaecology, University Hospitals Leuven, Leuven, Belgium
| | - Bernard Thienpont
- Laboratory for Functional Epigenetics, Department of Human Genetics, KU Leuven, Leuven, Belgium.
| |
Collapse
|
4
|
Khoiwal K, Gill P, Chawla L, Agrawal S, Chaturvedi J. What is your diagnosis? J Turk Ger Gynecol Assoc 2023; 24:76-78. [PMID: 36919689 PMCID: PMC10019005 DOI: 10.4274/jtgga.galenos.2022.2022-2-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022] Open
Affiliation(s)
- Kavita Khoiwal
- Department Obstetrics and Gynaecology, All India Institute of Medical Sciences (AIIMS), Rishikesh, India
| | - Poonam Gill
- Department Obstetrics and Gynaecology, All India Institute of Medical Sciences (AIIMS), Rishikesh, India
| | - Latika Chawla
- Department Obstetrics and Gynaecology, All India Institute of Medical Sciences (AIIMS), Rishikesh, India
| | - Shruti Agrawal
- Department Obstetrics and Gynaecology, All India Institute of Medical Sciences (AIIMS), Rishikesh, India
| | - Jaya Chaturvedi
- Department Obstetrics and Gynaecology, All India Institute of Medical Sciences (AIIMS), Rishikesh, India
| |
Collapse
|
5
|
Kahramanoglu Ö, Schiattarella A, Demirci O, Sisti G, Ammaturo FP, Trotta C, Ferrari F, Rapisarda AMC. Preeclampsia: state of art and future perspectives. A special focus on possible preventions. J OBSTET GYNAECOL 2022; 42:766-777. [PMID: 35469530 DOI: 10.1080/01443615.2022.2048810] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Abstract
Preeclampsia (PE) is characterised by the new onset of hypertension after the 20th week of pregnancy, with or without proteinuria or hypertension that leads to end-organ dysfunction. Since the only definitive treatment is delivery, PE still represents one of the leading causes of preterm birth and perinatal mobility and mortality. Therefore, any strategies that aim to reduce adverse outcomes are based on early primary prevention, prenatal surveillance and prophylactic interventions. In the last decade, intense research has been focussed on the study of predictive models in order to identify women at higher risk accurately. To date, the most effective screening model is based on the combination of anamnestic, demographic, biophysical and maternal biochemical factors. In this review, we provide a detailed discussion about the current and future perspectives in the field of PE. We will examine pathogenesis, risk factors and clinical features. Moreover, recent developments in screening and prevention strategies, novel therapies and healthcare management strategies will be discussed.
Collapse
Affiliation(s)
- Özge Kahramanoglu
- Department of Perinatology, Zeynep Kamil Education and Research Hospital, İstanbul, Turkey
| | - Antonio Schiattarella
- Department of Woman, Child and General and Specialized Surgery, University of Campania "Luigi Vanvitelli", Naples, Italy
| | - Oya Demirci
- Department of Perinatology, Zeynep Kamil Education and Research Hospital, İstanbul, Turkey
| | - Giovanni Sisti
- Department of Obstetrics and Gynecology, New York Health and Hospitals/Lincoln, Bronx, NY, USA
| | - Franco Pietro Ammaturo
- Department of Woman, Child and General and Specialized Surgery, University of Campania "Luigi Vanvitelli", Naples, Italy
| | - Carlo Trotta
- Department of Woman, Child and General and Specialized Surgery, University of Campania "Luigi Vanvitelli", Naples, Italy
| | - Federico Ferrari
- Department of Women's and Reproductive Health, University of Oxford, Oxford, UK
| | - Agnese Maria Chiara Rapisarda
- Department of General Surgery and Medical Surgical Specialties, Obstetrics and Gynecology Unit, University of Catania, Catania, Italy
| |
Collapse
|
6
|
Martinez C, González-Ramírez J, Marín ME, Martínez-Coronilla G, Meza-Reyna VI, Mora R, Díaz-Molina R. Isthmin 2 is decreased in preeclampsia and highly expressed in choriocarcinoma. Heliyon 2020; 6:e05096. [PMID: 33088937 PMCID: PMC7567920 DOI: 10.1016/j.heliyon.2020.e05096] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/15/2020] [Revised: 08/28/2020] [Accepted: 09/24/2020] [Indexed: 11/27/2022] Open
Abstract
Introduction Isthmin 2 (ISM2) is a protein which expression in humans is almost specific to the placenta. There is no previous report in the literature that investigated this protein in preeclampsia or choriocarcinoma. Methods We conducted a prospective, cross-sectional study that included women with preeclampsia, gestational hypertension and normotensive pregnancy. We measured serum concentrations of ISM2 protein and performed immunohistochemistry in placenta tissues. We also performed immunohistochemistry of ISM2 in samples from choriocarcinoma and compare with lung, prostate, colon, gastric and breast cancers. Results A total of 81 patients were included, 30 with preeclampsia, 21 with gestational hypertension and 30 controls. The ISM2 protein was found to be decreased in patients with preeclampsia compared to the control group (P = 0.036). These results were confirmed by immunohistochemistry. We also found that ISM2 protein was overexpressed in choriocarcinoma. Discussion Taken together, our results suggest an angiogenic function for ISM2. Its serum level decreased in our patients with preeclampsia could be reflecting that it is involved in the pathogenesis of the disease; on the other hand its high expression in choriocarcinoma, indicates that ISM2 may play an active role in the angiogenesis of this and other cancers.
Collapse
Affiliation(s)
- Cynthia Martinez
- Department of Obstetrics and Gynecology, Maternity and Children Hospital, Mexicali, B.C., 21376, Mexico
| | | | - María E Marín
- School of Medicine, University Autonomous of Baja California, Mexicali, B.C., 21000, Mexico
| | | | - Vanessa I Meza-Reyna
- Laboratory of Surgical Pathology and Cytodiagnosis, Mexicali, B.C., 21389, Mexico
| | - Rafael Mora
- Department of Obstetrics and Gynecology, Maternity and Children Hospital, Mexicali, B.C., 21376, Mexico.,Faculty of Nursing, University Autonomous of Baja California, Mexicali, B.C., 21100, Mexico.,School of Medicine, University Autonomous of Baja California, Mexicali, B.C., 21000, Mexico.,Laboratory of Surgical Pathology and Cytodiagnosis, Mexicali, B.C., 21389, Mexico
| | - Raul Díaz-Molina
- School of Medicine, University Autonomous of Baja California, Mexicali, B.C., 21000, Mexico
| |
Collapse
|
7
|
Taysi S, Tascan AS, Ugur MG, Demir M. Radicals, Oxidative/Nitrosative Stress and Preeclampsia. Mini Rev Med Chem 2019; 19:178-193. [DOI: 10.2174/1389557518666181015151350] [Citation(s) in RCA: 67] [Impact Index Per Article: 13.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/29/2016] [Revised: 11/01/2016] [Accepted: 02/28/2017] [Indexed: 12/23/2022]
Abstract
Preeclampsia (PE) has a profound effect in increasing both maternal and fetal morbidity and
mortality especially in third World. Disturbances of extravillous trophoblast migration toward uterine
spiral arteries is characteristic feature of PE, which, in turn, leads to increased uteroplacental vascular
resistance and by vascular dysfunction resulting in reduced systemic vasodilatory properties. Underlying
pathogenesis appeared to be an altered bioavailability of nitric oxide (NO•) and tissue damage
caused by increased levels of reactive oxygen species (ROS) and reactive nitrogen species (RNS). The
increase in ROS and RNS production or the decrease in antioxidant mechanisms generates a condition
called oxidative and nitrosative stress, respectively, defined as the imbalance between pro- and antioxidants
in favor of the oxidants. Additionally, ROS might trigger platelet adhesion and aggregation
leading to intravascular coagulopathy. ROS-induced coagulopathy causes placental infarction and impairs
the uteroplacental blood flow in PE. As a consequence of these disorders could result in deficiencies
in oxygen and nutrients required for normal fetal development resulting in fetal growth restriction.
On the one hand, enzymatic and nonenzymatic antioxidants scavenge ROS and protect tissues against
oxidative damage. More specifically, placental antioxidant enzymes including catalase, superoxide
dismutase (SOD), and glutathione peroxidase (GSH-Px) protect the vasculature from ROS, maintaining
the vascular function. On the other hand, ischemia in placenta in PE reduces the antioxidant activity.
Collectively, the extent of oxidative stress would increase and therefore leads to the development
of the pathological findings of PE including hypertension and proteinuria. Our goal in this article is to
review current literature about researches demonstrating the interplay between oxidative, nitrosative
stresses and PE, about their roles in the pathophysiology of PE and also about the outcomes of current
clinical trials aiming to prevent PE with antioxidant supplementation.
Collapse
Affiliation(s)
- Seyithan Taysi
- Department of Medical Biochemistry, Gaziantep University, Medical School, Gaziantep, Turkey
| | - Ayse Saglam Tascan
- Department of Medical Biochemistry, Gaziantep University, Medical School, Gaziantep, Turkey
| | - Mete Gurol Ugur
- Obstetrics and Gynecology, Gaziantep University, Medical School, Gaziantep, Turkey
| | - Mustafa Demir
- Division of Obstetrics and Gynecology, Golbasi State Hospital, Adiyaman, Turkey
| |
Collapse
|
8
|
Zhang Y, Zhang S, Huang W, Chen T, Yuan H, Zhang Y. Intermediate trophoblastic tumor: the clinical analysis of 62 cases and prognostic factors. Arch Gynecol Obstet 2019; 299:1353-1364. [DOI: 10.1007/s00404-018-05037-0] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/26/2018] [Accepted: 12/22/2018] [Indexed: 01/12/2023]
|
9
|
Chen J, Zhao L, Wang D, Xu Y, Gao H, Tan W, Wang C. Contribution of regulatory T cells to immune tolerance and association of microRNA‑210 and Foxp3 in preeclampsia. Mol Med Rep 2018; 19:1150-1158. [PMID: 30569125 PMCID: PMC6323262 DOI: 10.3892/mmr.2018.9733] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/06/2018] [Accepted: 11/02/2018] [Indexed: 12/22/2022] Open
Abstract
Increasing evidence suggests that an exaggerated maternal systemic inflammatofrery response may play a central role in the pathogenesis of preeclampsia (PE). Considering the growing evidence on microRNAs (miRNAs) and tissue‑specific regulators of gene expression, we investigated the potential association of miR‑210 and forkhead box p3 (Foxp3) in preeclamptic patients. Serum levels of the cytokines interleukin (IL)‑6, IL‑10, IL‑17, and transforming grown factor‑β1 were detected with ELISA. Reverse‑transcription‑quantitative polymerase chain reaction was performed to detect mRNA expression for maternal placenta retinoic acid‑related orphan receptor C, Foxp3 and miRNA (miR)‑210. Foxp3 protein expression was evaluated by western blot analysis. Serum levels of cytokines IL‑10 were significantly lower in preeclamptic patients than in normal pregnant women. mRNA expression of Foxp3 was significantly lower in placenta of PE. mRNA expression of miR‑210 was significantly increased in PE. Results of western blot analysis indicated that Foxp3 protein expression was lower in PE than in normal pregnant women. Our data suggest that PE manifests as a decreased number of regulatory T cells (Tregs), which regulate maternal tolerance of the fetus. In placenta from women with PE, compared with normal pregnant women, mRNA expression of Foxp3 was significantly decreased, and expression of miR‑210 was significantly increased.
Collapse
Affiliation(s)
- Jiying Chen
- Department of Obstetrics and Gynecology, Maternal and Children's Hospital of Shenzhen City, Southern Medical University, Shenzhen, Guangdong 518000, P.R. China
| | - Lijian Zhao
- Department of Obstetrics and Gynecology, Maternal and Children's Hospital of Shenzhen City, Southern Medical University, Shenzhen, Guangdong 518000, P.R. China
| | - Dengchuan Wang
- Department of Obstetrics and Gynecology, Shenzhen Longhua District Central Hospital, Shenzhen, Guangdong 518110, P.R. China
| | - Yanbin Xu
- Department of Obstetrics and Gynecology, Maternal and Children's Hospital of Shenzhen City, Southern Medical University, Shenzhen, Guangdong 518000, P.R. China
| | - Haijie Gao
- Department of Obstetrics and Gynecology, Maternal and Children's Hospital of Shenzhen City, Southern Medical University, Shenzhen, Guangdong 518000, P.R. China
| | - Wenqing Tan
- Department of Obstetrics and Gynecology, Shenzhen Longhua District Central Hospital, Shenzhen, Guangdong 518110, P.R. China
| | - Chenhong Wang
- Department of Obstetrics and Gynecology, Maternal and Children's Hospital of Shenzhen City, Southern Medical University, Shenzhen, Guangdong 518000, P.R. China
| |
Collapse
|
10
|
De Nola R, Schönauer LM, Fiore MG, Loverro M, Carriero C, Di Naro E. Management of placental site trophoblastic tumor: Two case reports. Medicine (Baltimore) 2018; 97:e13439. [PMID: 30508960 PMCID: PMC6283185 DOI: 10.1097/md.0000000000013439] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/01/2018] [Accepted: 11/05/2018] [Indexed: 11/27/2022] Open
Abstract
RATIONALE Placental site trophoblastic tumor (PSTT) is a very rare malignant tumor, belonging to a family of pregnancy-related illnesses, called gestational trophoblastic diseases (GTD). Less than 300 cases of PSTT have been reported in literature, with an incidence of ≈ 1/50,000-100,000 pregnancies representing only 0.23% to 3.00% of all GTDs. PATIENT CONCERNS Our report describes 2 additional cases of PSTT outlining their main diagnostic features and the subsequent management. The first case presented contemporary to a persistent hydatidiform mole in a 37-year-old woman, para 2042; whereas the second one originated 5 years after a miscarriage in 43-year-old woman, para 1031 with a previous diagnosis of breast cancer, and shared some features with placental site nodule (PSN), a benign condition. DIAGNOSIS The first case had a difficult diagnosis because there was an amenorrhea of 11th week with high serum beta-human chorionic gonadotropin (beta-HCG) and an initial ultrasound image of vesicular mole. After the Dilatation and Curettage, histology confirmed the previous hypothesis. However, the final histology of PSTT was obtained after major surgery. On the contrary, the diagnosis of the second case was less challenging but surprising, thanks to a routine trans-vaginal ultrasound showing a suspicious endometrial thickness positive for PSTT at a subsequent hysteroscopic guided biopsy. INTERVENTIONS The treatment consisted of hysterectomy and subsequent follow up. Lymphadenectomy or lymph node sampling were not performed due to the initial stage of the disease. OUTCOMES In the first case, there were high values of serum beta-HCG that plummeted after the surgery, whereas in the second one they had been always negative. Hereafter, both went through a follow up with periodic serum oncological markers, imaging studies and clinical evaluation, which have showed negative result for 3 years and 15 months, respectively. LESSONS A detailed gynecological ultrasound examination could be extremely helpful to understand the next diagnostic step of echo-guided D&C or hysteroscopic biopsy and for a pre-operative staging assessment. On the contrary, determining the serum beta-HCG's curve is crucial just in case of an initial positive value to pursue clinical evaluation and follow-up. In case of good prognostic factors, the main therapy remains hysterectomy.
Collapse
Affiliation(s)
- Rosalba De Nola
- Interdisciplinary Department of Medicine, Gynecology and Obstetrics Clinic, University of Bari
| | - Luca Maria Schönauer
- Interdisciplinary Department of Medicine, Gynecology and Obstetrics Clinic, University of Bari
| | - Maria Grazia Fiore
- Department of Emergency and Organ Transplantation, Pathology Unit, University of Bari, Bari, Italy
| | - Matteo Loverro
- Interdisciplinary Department of Medicine, Gynecology and Obstetrics Clinic, University of Bari
| | - Carmine Carriero
- Interdisciplinary Department of Medicine, Gynecology and Obstetrics Clinic, University of Bari
| | - Edoardo Di Naro
- Interdisciplinary Department of Medicine, Gynecology and Obstetrics Clinic, University of Bari
| |
Collapse
|
11
|
Nguyen Ba E, Golfier F, Malhaire C, Louafi L, Alran S. [Placental site trophoblastic tumor: When do we suspect it and which treatment shall we decide?]. ACTA ACUST UNITED AC 2016; 45:979-984. [PMID: 27692520 DOI: 10.1016/j.jgyn.2016.04.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/05/2016] [Revised: 04/12/2016] [Accepted: 04/26/2016] [Indexed: 11/25/2022]
Abstract
Tumors of trophoblast implantation site TTSI are rare gestational tumors. This case highlights the diagnostic difficulties and treatment of tumors of trophoblastic implantation site early. Patient of 28 years with no medical history, G1P1 who gave birth 11 months ago presented bleeding with an HCG level of 73IU that led to the diagnosis of early miscarriage. Treatment of miscarriage by hysteroscopy and curettage is complicated leading to the realization of an abdominopelvic CT and pelvic ultrasound that show an atypical uterine vascularity and an intracavitary heterogeneous mass. The pelvic MRI performed evokes a TTSI stage I. A hysterectomy with bilateral salpingectomy and ovarian conservation is achieved. Despite the standard treatment with surgery the HCG levels do not normalize before seven months after surgery. This indicates an adjuvant chemotherapy, the patient refuses. The presented case illustrates the diagnostic difficulties of the disease. He noted the importance of the second reading network proposed by the specialized center in Lyon. It also raises the question of adjuvant chemotherapy in some cases of early stage TTSI. The challenge is to define cases requiring adjuvant therapy. Predictors of chemotherapy in early stages could be tumor size, degree of infiltration of the myometrium and mutation p53. Amenorrhea, bleeding associated with uterine atypical vascularization, and atypical development of HCG<1000IU and/or unusual complications of treatment of miscarriage should evoke a tumor site trophoblastic implantation. Hysterectomy is the first treatment in early stages. Tumor size, degree of infiltration of the myometrium and mutation p53 are predictors to assess in multicentre studies to define the indications of postoperative chemotherapy.
Collapse
Affiliation(s)
- E Nguyen Ba
- Institut Curie Paris, 26, rue d'Ulm, 75005 Paris, France.
| | - F Golfier
- Centre des maladies trophoblastiques de Lyon, centre hospitalier Lyon-Sud, 165, chemin du Grand-Revoyet, 69495 Pierre-Bénite, France.
| | - C Malhaire
- Institut Curie Paris, 26, rue d'Ulm, 75005 Paris, France.
| | - L Louafi
- Institut Curie Paris, 26, rue d'Ulm, 75005 Paris, France.
| | - S Alran
- Institut Curie Paris, 26, rue d'Ulm, 75005 Paris, France.
| |
Collapse
|
12
|
Salzer L, Tenenbaum-Gavish K, Hod M. Metabolic disorder of pregnancy (understanding pathophysiology of diabetes and preeclampsia). Best Pract Res Clin Obstet Gynaecol 2015; 29:328-38. [DOI: 10.1016/j.bpobgyn.2014.09.008] [Citation(s) in RCA: 35] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/04/2014] [Accepted: 09/04/2014] [Indexed: 01/22/2023]
|
13
|
Mirza FG, Strohsnitter WC, Rivera J, Gyamfi-Bannerman C. Intrauterine growth restriction with abnormal umbilical artery Dopplers: a harbinger for preeclampsia? J Matern Fetal Neonatal Med 2012; 25:2658-61. [DOI: 10.3109/14767058.2012.704443] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
|
14
|
Sharma S, Norris WE, Kalkunte S. Beyond the threshold: an etiological bridge between hypoxia and immunity in preeclampsia. J Reprod Immunol 2010; 85:112-6. [PMID: 20236707 DOI: 10.1016/j.jri.2010.01.002] [Citation(s) in RCA: 29] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/10/2009] [Revised: 01/15/2010] [Accepted: 01/22/2010] [Indexed: 11/25/2022]
Abstract
Taking a cue from the recent workshop 'Preeclampsia--a Pressing Problem' sponsored by the National Institutes of Child Health and Human Development, this review article takes a fresh look at hypoxia and a dysfunctional immune system as the key contributors to the etiology of preeclampsia and the mechanisms involved therein. In the context of epidemiological research on the intricate and multifactorial nature of preeclampsia, we focus on hypoxia as an upstream regulator of preeclampsia and its consequences in a model compromised by a deficiency in key pregnancy compatible immune modulators. It has been proposed that placental hypoxia releases cytotoxic factors produced at the maternal-fetal interface into the circulation to manifest the maternal symptoms associated with preeclampsia. However, it is not clear how this mechanism is empowered in pregnant women. Does systemic hypoxia exert preeclampsia-like effects on pregnancy? Are these effects further manifested by intrinsic inflammation in the absence of key immune modulators such as IL-10? Thus, it is of paramount importance that in vivo models be developed wherein the role of systemic hypoxia can be evaluated for preeclampsia-causing events. We present a discussion on whether prolonged exposure to hypoxia can lead to a perpetual cycle of compartmentalized uteroplacental tissue damage, release of anti-angiogenic and vasoconstrictive factors that impair trophoblast invasion and promote systemic vascular resistance resulting in the maternal syndrome.
Collapse
Affiliation(s)
- Surendra Sharma
- Department of Pediatrics, Women and Infants Hospital, Warren Alpert Medical School of Brown University, Providence, RI 02905, USA.
| | | | | |
Collapse
|
15
|
Abstract
Gestational trophoblastic neoplasia (GTN) encompasses several entities including complete (CHM) and partial (PHM) hydatidiform mole (HM) and the malignant gestational trophoblastic tumors (GTTs), choriocarcinoma (CC), and placental-site trophoblastic tumor (PSTT), including epithelioid trophoblastic tumor (ETT). To detect pGTN, postmolar surveillance by measurement of maternal human chorionic gonoadotropin (hCG) levels should be performed. With such a protocol, many cases of pGTN are identified early at a presymptomatic stage based on plateuing or rising hCG concentrations and subsequently treated successfully with chemotherapy. In such cases, histopathological confirmation of the precise nature of the pGTN usually is not available. However, GTT also may present clinically with primary or metastatic disease, either following and unrecognized HM or developing from a nonmolar gestation. Due to their distinctive clinical and histological features, malignant GTTs are generally clearly subdivided into CC and PSTT (including ETT). CC essentially represents malignant trophoblastic tumors with differentiation toward villous trophoblast, with extensive hematogenous spread and high hCG levels, which are highly chemoresponsive. However, PSTTs, represent malignant differentiation toward implantation-site type trophoblast, with lower hCG levels and less response to chemotherapy. Current issues regarding the clinical and histological features of CC and PSTT/ETT are discussed.
Collapse
Affiliation(s)
- N J Sebire
- Trophoblastic Disease Unit, Charing Cross Hospital, London, and Department of Paediatric Pathology, Great Ormond Street Hospital, London WC1N 3JH, United Kingdom.
| | | |
Collapse
|
16
|
Struthmann L, Günthner-Biller M, Bergauer F, Friese K, Mylonas I. Complete hydatidiform mole in a perimenopausal woman with a subsequent severe thyriotoxicosis. Arch Gynecol Obstet 2008; 279:411-3. [PMID: 18642009 DOI: 10.1007/s00404-008-0734-0] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/07/2008] [Accepted: 07/08/2008] [Indexed: 10/21/2022]
Abstract
INTRODUCTION Gestational trophoblastic disease is one form of abnormal pregnancy, with a median maternal age of 27-28 years. One complication of trophoblastic disease is the development of a secondary hyperthyroidism, which resolves rapidly after evacuation of the hydatidiform mole. CASE REPORT We report a case of a 53-year-old woman presenting with a complete hydatidiform mole and who developed a severe thyrotoxicosis after suction evacuation of the hydatidiform mole. CONCLUSION A severe thyriotoxicosis can occur even after surgical evacuation of the mole. Therefore, evaluation of the thyroid function prior to operation, especially with a high quantitative hCG, should be performed to avoid severe complications.
Collapse
Affiliation(s)
- Lena Struthmann
- First Department of Obstetrics and Gynecology, Ludwig Maximilians University Munich, Maistrasse 11, 80337 Munich, Germany
| | | | | | | | | |
Collapse
|
17
|
MOODLEY M. Placental site trophoblastic tumor with antecedent molar pregnancy in association with human immunodeficiency virus infection. Int J Gynecol Cancer 2008; 18:860-1. [DOI: 10.1111/j.1525-1438.2007.01087.x] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
|
18
|
Behtash N, Karimi Zarchi M. Placental site trophoblastic tumor. J Cancer Res Clin Oncol 2007; 134:1-6. [PMID: 17701427 DOI: 10.1007/s00432-007-0208-y] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/05/2006] [Accepted: 03/23/2007] [Indexed: 10/23/2022]
Abstract
Placental site trophoblastic tumor (PSTT) is a rare neoplasm that rises from intermediate trophoblasts and commonly presents with low and variable concentration of HCG immunoactivity in serum, which can be difficult to differentiate from early stage choriocarcinoma/gestational trophoblastic neoplasm (GTN) or quiescent gestational trophoblastic disease. PSTT can occur after a normal pregnancy, spontaneous abortion, termination of pregnancy, ectopic or molar pregnancy. There is a wide clinical spectrum of presentation and behavior ranging from a benign condition to an aggressive disease with fatal outcome. Nontrophoblastic malignancies such as germ cell tumors or other tumors secreting low HCG must also be considered in the differential diagnosis. Because treatments for these conditions are different, a means of differentiating PSTT from other diagnoses is important. Surgery is the cornerstone of treatment. Chemotherapeutic regimen should be EMA/CO for first line chemotherapy; EMA/EP should be used in EMA/CO refractory cases. This article reviews the literatures on this rare but fatal disease.
Collapse
Affiliation(s)
- Nadereh Behtash
- Gynecology Oncology Department, Vali-asr Hospital, Tehran University of Medical Sciences, Imam Khomeini Hospital Complex, Keshavarz Boulevard, Tehran 14194, Iran.
| | | |
Collapse
|
19
|
Abstract
Gestational trophoblastic neoplasia comprises a unique group of human neoplastic diseases that derive from fetal trophoblastic tissues and represent semiallografts in patients. This group is composed of choriocarcinoma, placental-site trophoblastic tumour, and epithelioid trophoblastic tumour, and many forms are derived from the precursor lesions, hydatidiform moles. Although most patients with gestational trophoblastic neoplasia are cured by chemotherapy and tumour resection, some patients suffer from metastatic diseases that are refractory to conventional chemotherapy. Therefore, new therapeutic regimens are needed to reduce the toxic effects associated with current chemotherapy and to salvage the occasional non-operable patients with recurrent and chemoresistant disease. Until the fundamental biology of gestational trophoblastic neoplasia becomes more clearly understood, development of a new treatment will remain empirical. This review will briefly summarise the recent advances in understanding the molecular aetiology of this group of diseases and highlight the molecules that can be potentially used for therapeutic targets to treat metastatic gestational trophoblastic neoplasia.
Collapse
Affiliation(s)
- Ie-Ming Shih
- Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD, USA.
| |
Collapse
|
20
|
Erbil Y, Tihan D, Azezli A, Salmaslioğlu A, Ozlük Y, Büyükören A, Ozarmağan S. Severe hyperthyroidism requiring therapeutic plasmapheresis in a patient with hydatidiform mole. Gynecol Endocrinol 2006; 22:402-4. [PMID: 16864152 DOI: 10.1080/09513590600842372] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/24/2022] Open
Abstract
A 38-year-old woman had a 4-week history of vaginal bleeding, heat intolerance and palpitations. Levels of beta-human chorionic gonadotropin and thyroid hormones were abnormally high. After ultrasound diagnosis of a molar pregnancy, evacuation of the mole was planned with preoperative treatment involving the use of antithyroid drugs and plasmapheresis. Plasmapheresis was used to prepare for surgery in our patient who needed more rapid hormonal control. In conclusion, early diagnosis of molar pregnancy results in decreased incidence of significant complications related to hyperthyroidism.
Collapse
Affiliation(s)
- Yeşim Erbil
- Department of General Surgery, Medical Faculty, Istanbul University, Istanbul, Turkey.
| | | | | | | | | | | | | |
Collapse
|
21
|
Koc S, Ozdegirmenci O, Tulunay G, Ozgul N, Kose MF, Bulbul D. Recurrent partial hydatidiform mole: a report of a patient with three consecutive molar pregnancies. Int J Gynecol Cancer 2006; 16:940-3. [PMID: 16681793 DOI: 10.1111/j.1525-1438.2006.00232.x] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
Abstract
Hydatidiform mole (HM) is the most common form of gestational trophoblastic neoplasia and is characterized by atypical hyperplastic trophoblasts and hydropic villi. Recurrence of HM is extremely rare. Here, we report the case of a patient with three consecutive partial HMs without normal pregnancy. A 28-year-old woman with gravida 3, para 0, was referred to our hospital with a diagnosis of an invasive mole in December 2003. She had three consecutive molar pregnancies in 2000, 2001, and 2003. All three molar pregnancies were evacuated by suction curettage and the patient was followed by serial beta-human chorionic gonadotropin levels. All three moles were histologically confirmed as partial moles. In the first two molar events no additional treatment after evacuation was required, but in the last event, the beta-human chorionic gonadotropin levels increased and an invasive mole was suspected. Diagnostic workup ruled out an invasive mole and choriocarcinoma. Karyotypic analysis of the patient and her husband was normal. The patient required chemotherapy for treatment of persistent disease. Recurrent partial HM is a very rare clinical disorder. Repetitive molar pregnancy is not an indication for chemotherapy, but persistent disease does require chemotherapy.
Collapse
Affiliation(s)
- S Koc
- Department of Gynecological Oncology, SSK Maternity and Women's Health Teaching Hospital, Ankara, Turkey
| | | | | | | | | | | |
Collapse
|
22
|
Baergen RN, Rutgers JL, Young RH, Osann K, Scully RE. Placental site trophoblastic tumor: A study of 55 cases and review of the literature emphasizing factors of prognostic significance. Gynecol Oncol 2005; 100:511-20. [PMID: 16246400 DOI: 10.1016/j.ygyno.2005.08.058] [Citation(s) in RCA: 110] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/19/2005] [Accepted: 08/29/2005] [Indexed: 10/25/2022]
Abstract
OBJECTIVE The placental site trophoblastic tumor is a rare form of gestational trophoblastic disease. Fifteen percent of reported cases have been fatal, but predicting behavior in individual patients has been challenging. METHODS The clinical, gross and histopathological features of 55 cases and 180 cases in the literature were analyzed for their effect on survival and in relation to tumor stage. RESULTS The 55 patients in our series were 20 to 62 (average 32) years of age. The tumors occurred on an average of 34 months after the last known gestation. 84% were stage I, 2% stage II, 5% stage III, and 9% stage IV. Serum levels of human chorionic gonadotropin (hCG) were elevated (average 691 mIU/ml) in 77% of the cases. The tumors were on average 5 cm in greatest dimension and were composed microscopically of infiltrative sheets of intermediate (extravillous) trophoblastic cells. The mitotic rate ranged from 0 to 20 (average 5.0) per 10 high power fields. The follow-up interval averaged 4.6 years. Eight patients (15%) died from metastatic tumor, and nine additional patients had metastases or a recurrence but were alive at last contact. The most common metastatic sites were the lungs, liver, and vagina. CONCLUSIONS Significant factors associated with adverse survival in the present series were age over 35 years (P = 0.025), interval since the last pregnancy of over 2 years (P = 0.014), deep myometrial invasion (P = 0.006), stage III or IV (P < 0.0005), maximum hCG level > 1000 mIU/ml (P = 0.034), extensive coagulative necrosis (P = 0.024), high mitotic rate (P = 0.005), and the presence of cells with clear cytoplasm (P < 0.0005). Only stage and clear cytoplasm were independent predictors of overall survival, while stage and age were the only independent predictors of time to recurrence or disease-free survival. In the literature, factors associated with survival were stage (P < 0.005), interval from preceding pregnancy of over 2 years (P = 0.029), previous term pregnancy (P = 0.046), high mitotic rate (P < 0.0005), and high hCG level (P = 0.037).
Collapse
Affiliation(s)
- Rebecca N Baergen
- New York Presbyterian Hospital-Weill Cornell Medical Center, 520 East 70th Street, Starr 1002, New York, NY 10021, USA.
| | | | | | | | | |
Collapse
|